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ABSTRACT 
Purpose: We aimed to assess the associations of oxygen uptake at aerobic threshold (VO2 at AT) with 
cardiovascular and all-cause mortality.  
Design: VO2 at AT was assessed in 1,663 middle-aged men in a cohort study. Hazard ratios (HRs) were 
calculated for sudden cardiac death (SCD), fatal coronary heart disease (CHD) and cardiovascular disease 
(CVD), and all-cause mortality.  
Results: During a median follow-up of 25.6 years, 138 SCDs, 209 fatal CHDs, 333 fatal CVDs, and 719 
all-cause mortality events occurred. On adjustment for established risk factors, the HRs (95% CIs) for 
SCD, fatal CHD, fatal CVD, and all-cause mortality were 0.48 (0.28-0.82), 0.48 (0.31-0.74), 0.57 (0.41-
0.79), and 0.66 (0.53-0.82) respectively comparing extreme quartiles of VO2 at AT.  On further 
adjustment for peak VO2, the HRs were 0.87 (0.48-1.56), 0.83 (0.52-1.34), 0.91 (0.63-1.30), and 0.88 
(0.69-1.12) respectively. Addition of VO2 at AT to a standard CVD mortality risk prediction model was 
associated with a C-index change of 0.0085 (95% CI: -0.0002-0.0172; p=0.05) at 25 years. 
Conclusion: VO2 at AT is inversely associated with cardiovascular and all-cause mortality events, but the 
associations are partly dependent on peak VO2. VO2 at AT may improve the prediction of the long-term 
risk for CVD mortality.  
 
Keywords: oxygen uptake at aerobic threshold; cardiopulmonary exercise testing; cardiovascular disease; 
mortality; risk prediction 
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 KEY MESSAGES 
• Oxygen uptake at aerobic threshold (VO2 at AT), a cardiopulmonary exercise testing 
parameter, may be a useful prognostic tool for adverse clinical outcomes in the general 
population. 
• In a population-based prospective cohort study of men, VO2 at AT was inversely 
associated with cardiovascular and all-cause mortality events and improved the prediction 
of cardiovascular mortality. 
• In populations who cannot achieve maximal VO2, VO2 at AT may serve as a useful 
prognostic tool; however, further studies are warranted. 
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Introduction 
Maximal oxygen uptake (VO2max), commonly used as a measure of cardiorespiratory fitness (CRF), is 
considered the gold standard for assessing aerobic capacity.(1) VO2max is assessed using maximal-effort 
graded exercise testing and gas exchange analysis and has been commonly referred to as peak VO2 
(henceforth referred to as such) in clinical population studies, as some participants are not able to attain 
maximal aerobic capacity due to exercise limitations such as limb fatigue or pain.(2) The relationship 
existing between peak VO2, cardiovascular disease (CVD) and all-cause mortality has been well 
established. Consistently, several well-designed large-scale epidemiological studies have reported robust 
inverse and independent associations of peak VO2 with the risk of CVD,(3) all-cause mortality,(3) and 
mortality from vascular and non-vascular outcomes.(4, 5) Accumulating evidence also suggests that peak 
VO2 may improve CVD risk prediction above that of traditional cardiovascular risk factors.(3, 6) In 
certain situations where participants are not able to attain maximal aerobic capacity, peak VO2 may not 
accurately represent aerobic capacity(7) thereby limiting its prognostic value. Oxygen uptake at aerobic 
threshold (VO2 at AT) and VO2 at ventilatory threshold (VO2 at VT) are two additional cardiopulmonary 
exercise testing (CPX) parameters, which are also measures of exercise capacity and indices of cardiac 
and respiratory functioning. These parameters can be assessed by submaximal level exercise testing and 
during maximal exercise testing.(8) Both VO2 at AT and VO2 at VT are mainly influenced by the onset of 
lactic acidosis occurring at submaximal exercise intensities.(8, 9) However, whiles VO2 at AT 
corresponds to the first increase in blood lactate concentrations above resting levels during incremental 
exercise testing;(10) VO2 at VT represents the point reached during incremental exercise testing (intensity 
limit of prolonged activity),(9) beyond which a transition to anaerobic metabolism begins or where lactate 
clearance is no longer able to keep up with lactate production.(11) As reported in the 2016 update of 
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clinical recommendations for CPX by the European Society of Cardiology/European Association for 
Cardiovascular Prevention & Rehabilitation and the American Heart Association (AHA), peak VO2 and 
VO2 at VT have been consistently demonstrated to have prognostic significance in some specific patient 
populations.(12) We have recently shown strong linear and inverse associations of VO2 at VT with fatal 
cardiovascular and all-cause mortality outcomes, and the ability of VO2 at VT to significantly improve the 
prediction and classification of long-term CVD mortality risk beyond established cardiovascular risk 
factors in a general population setting.(13) Our overall data supported the conclusion that VO2 at VT may 
be a suitable proxy for peak VO2 in apparently healthy populations. Since aerobic exercise training 
improves CRF and aerobic capacity,(14) VO2 at AT may also be used as a proxy for peak VO2 to indicate 
the level of aerobic exercise capacity. However, there are no data available showing the relationships of 
VO2 at AT with fatal CVD and all-cause mortality outcomes. The prognostic significance of VO2 at AT 
for adverse outcomes is also unknown. VO2 at AT is a potentially useful and safe parameter which can be 
assessed from respiratory gases, as it can be defined at submaximal exercise levels with respiratory gas 
analyzers; compared to the assessment of peak VO2, which may difficult to determine sometimes due to 
exercise limitations. As previously evaluated for VO2 at VT, there is therefore a need to investigate if VO2 
at AT will be a useful prognostic tool for adverse clinical outcomes in apparently healthy populations. 
This will ultimately be of importance in improving the diagnostic value of clinical CPX testing. In this 
context, we aimed to evaluate the associations of VO2 at AT with the risk of sudden cardiac death (SCD), 
fatal coronary heart disease (CHD) and CVD events, and all-cause mortality in a population-based cohort 
of 1,663 apparently healthy middle-aged men from eastern Finland.  
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Materials and methods  
Study design and population 
Study participants included a representative sample of men living in the city of Kuopio and its 
surrounding rural communities in eastern Finland, who were recruited into the Kuopio Ischemic Heart 
Disease (KIHD) risk factor study. This prospective population-based cohort study was designed to 
investigate potential risk factors for atherosclerotic CVD and other related chronic disease outcomes. 
Participants were men aged 42-61 years during baseline examinations performed between March 1984 
and December 1989. There was a total of 3433 randomly selected men who were potentially eligible and 
of these, 3235 were eligible for inclusion into the study. Of the 3235 men, 2682 (82.9 %) volunteered to 
participate and 553 declined to give informed consent or did not respond to the invitation. The current 
analysis included 1,663 men with complete information on VO2 at AT, covariates, and specified 
outcomes. The study protocol and design was approved by Research Ethics Committee of the University 
of Eastern Finland, Kuopio, Finland. Each participant included in the study provided written informed 
consent.  
 
Assessment of oxygen uptake at aerobic threshold 
A submaximal symptom-limited exercise tolerance test was performed between 8:00 am and 10:00 am 
using an electronic braked cycle ergometer.(15) Oxygen uptake was assessed using a respiratory gas 
analyzer (Medical Graphics, MCG, St. Paul, Minnesota) during a submaximal symptom-limited cycle 
ergometer exercise tolerance test. The analyzer expressed VO2 as an average value recorded over 8 
seconds. All exercise tests were conducted under the supervision of an experienced physician and assisted 
by an experienced nurse to ensure safety. 
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The main exposure variable of the current study using CPX data was VO2 at AT which refers to the 
aerobic gas exchange threshold, indicating the first increase in blood lactate concentration leading to an 
over-proportional increase in carbon dioxide (CO2) output as related to O2 uptake increase due to the 
bicarbonate buffering of the proton resulting from the dissociation of lactic acid.(10) The threshold (VO2 
at AT) was defined from essential respiratory gas exchange changes. There is a compensatory increased 
stimulus for pulmonary ventilation mediated via carotid bodies as a consequence of a rising CO2 partial 
pressure. In addition, pulmonary minute ventilation was increasing over-proportionally first time during 
increased exercise intensity at the VO2 at AT. After an initial linear relationship between increased 
exercise workload and respiratory gases exchange increase (VO2 and VCO2), there is sudden upward bend 
indicating that excess CO2 has been exhaled during increasing exercise workload. The intersection 
between two linear lines of respiratory gases (VO2  and CO2) for the upper and the lower part of the 
function indicates VO2 at AT which is, by definition, an oxygen uptake. In this population study, the 
definition of aerobic threshold was solely based on changes in respiratory gases as reported 
previously,(10) which is a non-invasive approach using a visual and graphical methodology of respiratory 
gases. Graphical determination was done by plotting VCO2 on the y-axis and VO2 on the x-axis. VO2 at 
AT was expressed as an absolute amount i.e in ml/min. 
 
Assessment of risk markers 
Blood sample collection, physical measurements, assessment of lifestyle characteristics, and measurement 
of serum lipids, lipoproteins and other biochemical characteristics have been described in detail in 
previously published reports.(16, 17) In brief, the cholesterol content of lipoprotein fractions were 
measured from fresh samples after combined ultracentrifugation and precipitation and serum triglycerides 
were assessed enzymatically (Boehringer Mannheim, Mannheim, Germany).(16) The glucose 
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dehydrogenase method (Merck, Darmstadt, Germany) was used to measure fasting plasma glucose after 
protein precipitation by trichloroacetic acid.(18) Self-administered questionnaires were used to assess 
smoking, alcohol consumption, blood pressure, use of medication, and baseline diseases,(16) all of which 
have been described previously.(19-21)  Adulthood socioeconomic status (SES) was assessed as a 
combined measure of income, education, occupation, occupational prestige, material standard of living, 
and housing conditions.(22) Peak VO2 was used as a measure of CRF, which was assessed by using a 
respiratory gas exchange analyzer during the cycle ergometer exercise test. A detailed description of the 
measurement of peak VO2 has been reported elsewhere.(15) Peak VO2 was also expressed in ml/min. 
 
Ascertainment of outcomes 
All deaths that occurred from study enrollment through to 2013 were included. There were zero losses to 
follow-up recorded in the KIHD study. Participants are under continuous annual surveillance for the 
development of new cardiovascular events, which include incident cases and deaths.(23) The sources of 
information on all outcomes were based on a comprehensive review of all available hospital records, 
questionnaires administered to health workers, wards of healthcare centres or hospitals, interviews with 
informants, electrocardiograms of study participants, registers of deaths as well as death certificates, and 
medico-legal reports. Sudden cardiac deaths were diagnosed and classified based on presenting 
complaints, electrocardiographic findings, cardiac enzyme levels, findings of autopsies (80% of all 
cardiac deaths), and history of CHD as well as the clinical history and findings reported from hospital and 
by paramedics. Sudden cardiac death was diagnosed when the death occurred within an hour of the onset 
of an abrupt change in symptoms or within 24 hours after the onset of symptoms; including those cases 
not witnessed when clinical and autopsy findings did not reveal a non-cardiac cause of sudden death or 
after successful resuscitation from ventricular tachycardia and/or ventricular fibrillation.(5) Coronary 
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heart disease and CVD deaths were coded using the International Classification of Diseases, Ninth 
Revision (ICD-9), and International Statistical Classification of Diseases, 10th Revision (ICD-10), codes. 
Two physicians cross-checked the documents in great detail. The Independent Events Committee of the 
KIHD study, blinded to clinical data, performed classification of all outcomes. 
 
Statistical analysis 
Descriptive analyses were conducted to summarize the baseline characteristics of the participants. We 
calculated age-adjusted partial correlation coefficients to assess the cross-sectional associations of VO2 at 
AT with several risk factors and markers. Hazard ratios (HRs) with 95% confidence intervals (CIs) for 
SCD, fatal CHD and CVD events, and all-cause mortality were estimated using Cox proportional hazard 
models. Schoenfeld residuals were used to confirm the assumptions of the proportionality of hazards.(24)  
To assess the shape of the relationship between VO2 at AT and each outcome, HRs were calculated within 
quartiles of baseline VO2 at AT and plotted against mean values of VO2 at AT within each quartile. 
Floating variances were used to calculate 95% CIs for the log hazard ratio in each group (including the 
reference group), to allow for comparisons across the groups irrespective of the arbitrarily chosen 
reference category (bottom quartile).(25) VO2 at AT was modelled as both continuous [per standard 
deviation (SD) increase] and categorical (quartiles) variables. Hazard ratios were progressively adjusted 
for age; other traditional cardiovascular risk factors [body mass index (BMI), systolic blood pressure 
(SBP), high-density lipoprotein cholesterol (HDL-C), alcohol consumption, history of diabetes mellitus, 
smoking status, prevalent CHD, resting heart rate, physical activity, and SES]; and finally peak VO2. 
Collinearity diagnostics employing the variance inflation factor (VIF)(26) showed no evidence of 
collinearity between VO2 at AT and peak VO2 (VIF=1.58). We performed subgroup analyses using tests 
of interaction to assess statistical evidence of any differences in hazard ratios across levels/categories of 
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pre-specified individual level characteristics, including age at survey, BMI, SBP, HDL-C, history of 
diabetes mellitus, smoking status, and prevalent CHD. Sensitivity analysis involved excluding the first 
five years of follow-up.  
To evaluate whether adding information on VO2 at AT to conventional cardiovascular risk factors 
would be associated with an improvement in the prediction of CVD mortality risk, we calculated 
measures of discrimination for censored time-to-event data (Harrell’s C-index (27)) and 
reclassification.(28, 29) To investigate the change in C-index on the addition of VO2 at AT, two CVD 
mortality risk prediction models were fitted: one model based on traditional risk factors (i.e., age, SBP, 
history of diabetes, total cholesterol, HDL-C, and smoking) and the second model with these risk factors 
plus VO2 at AT. Because there were too few deaths at 10 years, the incremental predictive value of VO2 
at AT for the 25-year risk of CVD mortality was rather examined. Reclassification analysis was restricted 
to the first 25 years of follow-up and was assessed using the net-reclassification-improvement (NRI)(28, 
29) and integrated-discrimination-improvement (IDI)(28) by comparing the model containing 
conventional risk factors  to the predicted risk from the model containing conventional risk factors plus 
VO2 at AT. Reclassification analysis was based on predicted 25-year CVD mortality risk categories of 
low (<8%), intermediate (8 to <30%), and high (≥30%) risk as previously reported.(30) All statistical 
analyses were conducted using Stata version 14 (Stata Corp, College Station, Texas). 
 
Results 
Baseline characteristics and correlates of VO2 at AT 
The mean age and BMI at study entry were 52 [standard deviation (SD), 5] years and 27.0 (SD, 3.5) 
kg/m2 respectively. The mean (SD) value of VO2 at AT at baseline was 1,267 (321) ml/min (Table 1). 
Weak to moderate inverse correlations were observed for values of VO2 at AT and lipids (total cholesterol 
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and triglycerides). Weak positive correlations were observed for physical measures (BMI and physical 
activity), HDL-C, and serum creatinine lipids. VO2 at AT was strongly correlated with peak VO2 (r = 
0.64) in age-adjusted analysis. The strong association remained the same in correlational analysis further 
adjusted for BMI. Values of VO2 at AT were significantly lower in men with diabetes compared with 
men without diabetes, smokers compared to non-smokers, and men with prevalent CHD compared to men 
without prevalent CHD. During a median (IQR) follow-up of 25.6 (20.1-27.1) years (37,496 person-years 
at risk), a total of 138 SCDs, 209 fatal CHDs, 333 fatal CVDs, and 719 all-cause mortality events were 
recorded. 
 
VO2 at AT and outcome events 
In analyses adjusted for several established risk factors (age, BMI, SBP, HDL-C, alcohol consumption, 
history of diabetes mellitus, smoking status, prevalent CHD, resting heart rate, physical activity, and 
SES), VO2 at AT was linearly and inversely associated with SCD, fatal CHD, fatal CVD, and all-cause 
mortality (Figure 1). Table 2 shows the associations of VO2 at AT with each outcome assessed. The age-
adjusted HRs (95% CIs) 1 SD increase in VO2 at AT for SCD, fatal CHD, fatal CVD, and all-cause 
mortality were 0.64 (0.53-0.77), 0.65 (0.56-0.76), 0.75 (0.66-0.84), and 0.82 (0.75-0.88) respectively. 
These were only minimally attenuated to 0.70 (0.57-0.85), 0.70 (0.59-0.81), 0.79 (0.70-0.89), and 0.85 
(0.79-0.92) respectively after adjustment for established cardiovascular risk factors. The associations were 
less robust on further adjustment for peak VO2. Alternatively, comparing the top versus bottom quartile of 
VO2 at AT, the age-adjusted HRs (95% CIs) for SCD, fatal CHD, fatal CVD, and all-cause mortality were 
0.37 (0.22-0.62), 0.39 (0.25-0.59), 0.48 (0.35-0.67), and 0.57 (0.46-0.71) respectively.  After adjustment 
for established cardiovascular risk factors, the corresponding hazard ratios were 0.48 (0.28-0.82), 0.48 
(0.31-0.74), 0.57 (0.41-0.79), and 0.66 (0.53-0.82) respectively. On further adjustment for peak VO2, the 
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corresponding HRs were attenuated to 0.87 (0.48-1.56), 0.83 (0.52-1.34), 0.91 (0.63-1.30), and 0.88 
(0.69-1.12) respectively (Table 2). Generally, the associations demonstrated did not vary significantly by 
levels or categories of several clinically relevant characteristics (Figures 2 and 3). However, for all 
outcomes except for SCD, there was some evidence of effect modification by SBP (p for interaction for 
all < 0.05). Stronger inverse associations were observed in men with lower SBP (< 133 mmHg) compared 
to weaker or modest associations in men with higher SBP (≥ 133 mmHg). There was also evidence of 
effect modification by history of CHD and smoking status for the association of VO2 at AT with SCD (p 
for interaction for all < 0.05). While statistically significant inverse associations were observed in men 
with a history of CHD and current smokers, there were weak or modest associations for men without a 
history of CHD and non-smokers (Figure 3). To put the strength of the associations of VO2 at AT with 
the risk of all outcomes assessed into context, direct comparisons were made to associations of peak VO2 
with these outcomes. Peak VO2 was inversely and independently associated with each outcome. The 
associations were also independent of VO2 at AT (Table 3). 
 
VO2 at AT and CVD mortality risk prediction 
A CVD mortality risk prediction model containing conventional risk factors yielded a C-index of 0.7070 
(95% CI: 0.6795-0.7345; p<0.001). After addition of VO2 at AT measurements to this prognostic model, 
the C-index increased by 0.0085 (95% CI: -0.0002-0.0172; p=0.05) and yielded an overall NRI of 2.78% 
(-0.65-6.22%; p=0.11) for the predicted 25-year CVD mortality risk categories. The IDI was 0.0071 
(0.0028-0.0115; p=0.001). 
To compare the predictive ability of VO2 at AT with peak VO2 in the same sample, information on 
peak VO2 was added to the model containing conventional risk factors. There was a C-index change of 
0.0191 (95% CI: 0.0046-0.0336; p=0.01). After taking into account inappropriate reclassification, there 
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was a significant improvement in the classification of participants into predicted 25-year CVD mortality 
risk categories (NRI: 5.51%, 0.56-10.47%; p=0.03). The IDI was 0.0257 (0.0168-0.0345; p<0.001). 
 
Discussion 
Although previous population studies including the KIHD cohort have consistently shown higher CRF (as 
measured by peak VO2) to be protective of fatal cardiovascular and all-cause mortality events, the 
associations of VO2 at AT with these outcomes have not been previously evaluated. In this population of 
middle-aged Finnish men, we have shown for the first time that this submaximal exercise test parameter 
is strongly, linearly, and inversely associated with the risk of SCD, fatal CHD and CVD, and all-cause 
mortality in analyses adjusted for established cardiovascular risk factors.  The associations were however 
attenuated after further adjustment for peak VO2. There were modest inverse correlations of VO2 at AT 
with several established cardiovascular risk factors. As expected, VO2 at AT was strongly correlated with 
peak VO2. In contrast, the inverse association between peak VO2 and each outcome was independent of 
VO2 at AT in analyses conducted in the same participants, which suggests peak VO2 as a stronger risk 
indicator than VO2 at AT. Except for evidence of effect modification by SBP, smoking status, and history 
of CHD, the associations of VO2 at AT with outcomes remained generally consistent across several 
clinically relevant subgroups. The association was stronger in men with a history of CHD compared to 
men without a history of CHD, reflecting existing evidence which suggests that aerobic exercise capacity 
has more beneficial effects on mortality risk in individuals with pre-existing cardiometabolic disease 
compared to individuals without pre-existing.(31, 32) Our results suggest that VO2 at AT may be an 
important determinant of fatal cardiovascular and all-cause mortality events. Furthermore, addition of 
VO2 at AT was associated with a marginally statistically significant improvement in CVD mortality 
prediction beyond traditional risk factors; however, the incremental benefit was small. Addition of 
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information on VO2 at AT was not associated with significant improvement in reclassification of 
participants across clinically meaningful risk categories. Further analyses in the same set of participants 
showed the improvement provided by peak VO2 assessment in prediction of CVD mortality risk was 
better than that of VO2 at AT.  
Among these three CPX variables – peak VO2, VO2 at VT, and VO2 at AT – the prognostic values of 
peak VO2 and VO2 at VT have been assessed extensively in the literature, whereas there is very limited 
data on VO2 at AT. In a recent study, we have investigated the association of VO2 at VT with fatal 
cardiovascular and all-cause mortality outcomes as well as its prognostic value in a general male 
Caucasian population.(13) In the current study, using VO2 at AT as our exposure, we have replicated the 
same objectives as investigated previously. Our main exposure was VO2 at AT which represents aerobic 
gas exchange at submaximal exercise levels as assessed by the first increase in blood lactate 
concentration; which is indicated by an over-proportional increase in CO2 output as related to O2 uptake 
increase due to the bicarbonate buffering of the proton resulting from the dissociation of lactic acid. Both 
VO2 at AT and VO2 at VT can be assessed at submaximal levels reflecting endurance exercise capacity 
which can be improved by regular exercise training.(10)  
Several mechanisms have been postulated to underpin the protective effects of CRF on cardiovascular 
and all-cause mortality outcomes; and these include both physiological and metabolic processes.(33) 
Given that VO2 at AT is a measure of aerobic exercise capacity and therefore an index of the level of 
physical activity, we hypothesize that these same mechanistic processes may underlie the associations 
demonstrated. Physical activity improves aerobic exercise capacity, which ultimately confers long-term 
benefits on the cardiovascular system. Indeed, it has been shown that moderate intensity regular exercise 
for at least 6 months can improve aerobic exercise capacity by 1 metabolic equivalent (MET).(34) 
Physical activity exhibits several suggested beneficial effects on cardiovascular function and these 
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include: (i) beneficial modulation of cardiovascular risk factors including markers of subclinical heart 
disease such as natriuretic peptides and cardiac troponin T(35, 36); (ii) increase in cardiac output, left 
ventricular function, oxygen utilization, and the formation of collateral vessels;(37, 38) (iii) regulation of 
cardiac autonomic function and vagal control of heart rate;(39) and (iv) anti-inflammatory effects, by 
reduction in levels of risk markers such as C-reactive protein,(40, 41) which is associated with an 
increased risk of cardiovascular and all-cause mortality outcomes.(42) Physical activity may also improve 
endothelial function, blood pressure and lipid levels, thus preventing or retarding the atherosclerotic 
process.(37, 43) The findings of graded and independent associations between VO2 at AT and the 
outcomes assessed are consistent with indications of causal relationships, but these will require robust 
evidence from intervention studies. Cardiorespiratory fitness is known to be influenced by both genetic as 
well as environmental factors, with physical activity accounting for a greater part of the variation.(44) 
Though physical activity improves CRF, this depends on several factors such as baseline health and 
fitness status, type, duration, and intensity of physical activity, as well as familial factors. Given that these 
same reasons may relate to our exposure (VO2 at AT), exercise trials may not enable causal inferences, as 
interventions that improve VO2 at AT will interact with initial physical fitness levels as well as 
cardiovascular risk factors in modulating the risk of outcomes to be ascertained. In the absence of clinical 
trials however, Mendelian randomisation studies of genetic variants related to VO2 at AT may provide 
another route to assess causality.(45) It has been reported that genetic factors account for 25-40% of the 
variation in CRF,(44) although the genetic contribution to the level of VO2 at AT has not been well 
studied. 
As demonstrated in our previous study which reported strong inverse and independent associations of 
VO2 at VT with fatal cardiovascular and all-cause mortality outcomes;(13) the current findings also 
highlight a protective effect of VO2 at AT on fatal cardiovascular and all-cause mortality outcomes. The 
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continuous nature of the association between VO2 at AT and CVD mortality and the findings from risk 
prediction analyses suggest that VO2 at AT may be potentially suitable for population-level risk 
assessment. However, the improvements provided by VO2 at AT in risk prediction and reclassification 
were modest and may not be clinically meaningful. In a head-to-head comparison, we compared 
incremental improvements afforded by VO2 at AT assessment with those afforded by peak VO2. In 
addition to being a stronger risk indicator, peak VO2 also provides better improvement in the prediction of 
CVD mortality risk than VO2 at AT. The overall results show that information on VO2 at AT cannot be 
used to replace peak VO2, but may be used as an alternative or proxy for peak VO2 in subjects unable to 
achieve peak VO2. Given that CPX parameters (such as VO2 at AT and VO2 at VT) are still being 
underutilized, there have been recommendations for continued research into their clinical utility across all 
patient populations.(12)  Given that this is the first study on the topic, data from future studies are needed 
to establish any role of VO2 at AT in CVD risk assessment and prevention in general and specific patient 
populations.  
 
Strengths and limitations 
Several notable strengths of the current study deserve consideration. This is the first prospective 
evaluation of the associations between VO2 at AT and the risk of cardiovascular and all-cause mortality 
outcomes. Our analyses employed a well characterized large cohort, which involved a high response rate, 
a long follow-up period, and there were no losses during follow-up. Our sample was selected to be a 
nationally representative population-based cohort of middle-aged Finnish men, making it possible to 
generalize the results in male populations. Participants in this study have undergone annual monitoring 
and outcomes have been checked using well-linked established databases for outcomes.(5, 6) We 
recorded information on various CVD outcomes using validated endpoint definitions. We had access to a 
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comprehensive panel of lifestyle and biological markers, allowing adequate adjustment for potential 
confounders. Our analyses were comprehensive and the observed associations are robust. Our results 
showed consistent associations across several clinically relevant subgroups. There were a number of 
limitations which also deserve consideration. The KIHD study included middle-aged men based on a 
genetically and an ethnically homogeneous population from eastern Finland and therefore our findings 
cannot be extrapolated widely to women and other ethnicities. Given the population-based nature of the 
study, VO2 at AT assessment was based on respiratory gas changes methodology, as blood samples with 
the assessment of lactic acid was not available during CPX. A one-time assessment of VO2 at AT was 
used and therefore we could not correct for regression dilution. The assessment based on baseline 
measurements could have under-estimated our associations as reproducibility substudies of peak VO2 in 
the KIHD study have reported high within-person variability in peak VO2 levels.(46) 
 
Conclusions 
This prospective study shows strong linear and inverse associations of VO2 at AT with cardiovascular and 
all-cause mortality outcomes, which are partly dependent on peak VO2. In addition, VO2 at AT 
significantly improves the prediction of the long-term risk for CVD mortality when added to established 
risk factors. However, peak VO2 remained the best indicator and predictor of risk and VO2 at AT could 
be used as a proxy should peak VO2 not be achieved. 
 
Acknowledgments 
We thank the staff of the Kuopio Research Institute of Exercise Medicine and the Research Institute of 
Public Health and University of Eastern Finland, Kuopio, Finland for the data collection in the study. 
 
 18 
 
 
 
 
Disclosure of interest 
The authors report no conflicts of interest 
 
Funding 
This work has been supported in part by grants from the Finnish Foundation for Cardiovascular Research, 
Helsinki, Finland. The funders had no role in study design, data collection and analysis, decision to 
publish or preparation of the manuscript. 
 
 
 
  
 19 
 
 
 
 
References 
 
1. Noonan V, Dean E. Submaximal exercise testing: clinical application and interpretation. Phys Ther. 
2000;80(8):782-807. 
2. American College of Sports Medicine (ACSM). ACSM’s guidelines for exercise testing and 
prescription. 9th ed. Philadephia, PA: Lippincott Williams & Wilkins; 2014. 
3. Kodama S, Saito K, Tanaka S, Maki M, Yachi Y, Asumi M, et al. Cardiorespiratory fitness as a 
quantitative predictor of all-cause mortality and cardiovascular events in healthy men and women: a meta-
analysis. Jama. 2009;301(19):2024-35. 
4. Hagnas MJ, Kurl S, Rauramaa R, Lakka TA, Makikallio TH, Savonen K, et al. The value of 
cardiorespiratory fitness and exercise-induced ST segment depression in predicting death from coronary 
heart disease. Int J Cardiol. 2015;196:31-3. 
5. Laukkanen JA, Makikallio TH, Rauramaa R, Kiviniemi V, Ronkainen K, Kurl S. Cardiorespiratory 
fitness is related to the risk of sudden cardiac death: a population-based follow-up study. J Am Coll 
Cardiol. 2010;56(18):1476-83. 
6. Laukkanen JA, Kurl S, Salonen R, Rauramaa R, Salonen JT. The predictive value of 
cardiorespiratory fitness for cardiovascular events in men with various risk profiles: a prospective 
population-based cohort study. European Heart Journal. 2004;25(16):1428-37. 
7. Marzolini S, Oh P, McIlroy W, Brooks D. The effects of an aerobic and resistance exercise training 
program on cognition following stroke. Neurorehabil Neural Repair. 2013;27(5):392-402. 
8. Balady GJ, Arena R, Sietsema K, Myers J, Coke L, Fletcher GF, et al. Clinician's Guide to 
cardiopulmonary exercise testing in adults: a scientific statement from the American Heart Association. 
Circulation. 2010;122(2):191-225. 
9. Guazzi M, Adams V, Conraads V, Halle M, Mezzani A, Vanhees L, et al. EACPR/AHA Scientific 
Statement. Clinical recommendations for cardiopulmonary exercise testing data assessment in specific 
patient populations. Circulation. 2012;126(18):2261-74. 
10. Meyer T, Lucia A, Earnest CP, Kindermann W. A conceptual framework for performance 
diagnosis and training prescription from submaximal gas exchange parameters--theory and application. 
Int J Sports Med. 2005;26 Suppl 1:S38-48. 
11. Wasserman K, Whipp BJ, Koyl SN, Beaver WL. Anaerobic threshold and respiratory gas exchange 
during exercise. J Appl Physiol. 1973;35(2):236-43. 
12. Guazzi M, Arena R, Halle M, Piepoli MF, Myers J, Lavie CJ. 2016 focused update: clinical 
recommendations for cardiopulmonary exercise testing data assessment in specific patient populations. 
Eur Heart J. 2016. 
 20 
 
 
 
 
13. Kunutsor SK, Kurl S, Khan H, Zaccardi F, Laukkanen JA. Associations of cardiovascular and all-
cause mortality events with oxygen uptake at ventilatory threshold. Int J Cardiol. 2017. 
14. Skinner JS, Wilmore KM, Krasnoff JB, Jaskolski A, Jaskolska A, Gagnon J, et al. Adaptation to a 
standardized training program and changes in fitness in a large, heterogeneous population: the 
HERITAGE Family Study. Med Sci Sports Exerc. 2000;32(1):157-61. 
15. Lakka TA, Venalainen JM, Rauramaa R, Salonen R, Tuomilehto J, Salonen JT. Relation of leisure-
time physical activity and cardiorespiratory fitness to the risk of acute myocardial infarction. N Engl J 
Med. 1994;330(22):1549-54. 
16. Salonen JT, Nyyssonen K, Korpela H, Tuomilehto J, Seppanen R, Salonen R. High stored iron 
levels are associated with excess risk of myocardial infarction in eastern Finnish men. Circulation. 
1992;86(3):803-11. 
17. Kunutsor SK, Khan H, Laukkanen JA. gamma-Glutamyltransferase and Risk of Sudden Cardiac 
Death in Middle-Aged Finnish Men: A New Prospective Cohort Study. J Am Heart Assoc. 2016;Feb 
8;5(2). pii: e002858. doi: 10.1161/JAHA.115.002858.(2). 
18. Salonen JT. Is there a continuing need for longitudinal epidemiologic research? The Kuopio 
Ischaemic Heart Disease Risk Factor Study. Ann Clin Res. 1988;20(1-2):46-50. 
19. Kunutsor SK, Khan H, Laukkanen JA. Serum albumin concentration and incident type 2 diabetes 
risk: new findings from a population-based cohort study. Diabetologia. 2015;58(5):961-7. 
20. Kunutsor SK, Khan H, Nyyssonen K, Laukkanen JA. Lipoprotein(a) and risk of sudden cardiac 
death in middle-aged Finnish men: A new prospective cohort study. Int J Cardiol. 2016;220:718-25. 
21. Kunutsor SK, Laukkanen JA. Gamma glutamyltransferase and risk of future dementia in middle-
aged to older Finnish men: A new prospective cohort study. Alzheimer's & dementia : the journal of the 
Alzheimer's Association. 2016. 
22. Yang S, Lynch JW, Raghunathan TE, Kauhanen J, Salonen JT, Kaplan GA. Socioeconomic and 
psychosocial exposures across the life course and binge drinking in adulthood: population-based study. 
American journal of epidemiology. 2007;165(2):184-93. 
23. Karppi J, Kurl S, Makikallio TH, Ronkainen K, Laukkanen JA. Serum beta-carotene concentrations 
and the risk of congestive heart failure in men: A population-based study. Int J Cardiol. 
2013;168(3):1841-6. 
24. Therneau TM, Grambsch PM. Modeling Survival Data: Extending the Cox Model. New York: 
Springer; 2000. 
25. Kunutsor SK, Bakker SJ, James RW, Dullaart RP. Serum paraoxonase-1 activity and risk of 
incident cardiovascular disease: The PREVEND study and meta-analysis of prospective population 
studies. Atherosclerosis. 2015;245:143-54. 
 21 
 
 
 
 
26. Lazo M, Selvin E, Clark JM. Brief communication: clinical implications of short-term variability in 
liver function test results. Ann Intern Med. 2008;148(5):348-52. 
27. Harrell FE, Jr., Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, 
evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med. 1996;15(4):361-87. 
28. Pencina MJ, D'Agostino RB, Sr., D'Agostino RB, Jr., Vasan RS. Evaluating the added predictive 
ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med. 
2008;27(2):157-72; discussion 207-12. 
29. Pencina MJ, D'Agostino RB, Sr., Steyerberg EW. Extensions of net reclassification improvement 
calculations to measure usefulness of new biomarkers. Statistics in Medicine. 2011;30(1):11-21. 
30. Gupta S, Rohatgi A, Ayers CR, Willis BL, Haskell WL, Khera A, et al. Cardiorespiratory fitness 
and classification of risk of cardiovascular disease mortality. Circulation. 2011;123(13):1377-83. 
31. Faselis C, Doumas M, Panagiotakos D, Kheirbek R, Korshak L, Manolis A, et al. Body mass index, 
exercise capacity, and mortality risk in male veterans with hypertension. Am J Hypertens. 
2012;25(4):444-50. 
32. Kokkinos P, Doumas M, Myers J, Faselis C, Manolis A, Pittaras A, et al. A graded association of 
exercise capacity and all-cause mortality in males with high-normal blood pressure. Blood Press. 
2009;18(5):261-7. 
33. Physical activity and cardiovascular health. NIH Consensus Development Panel on Physical 
Activity and Cardiovascular Health. Jama. 1996;276(3):241-6. 
34. Kurl S, Laukkanen JA, Rauramaa R, Lakka TA, Sivenius J, Salonen JT. Cardiorespiratory fitness 
and the risk for stroke in men. Arch Intern Med. 2003;163(14):1682-8. 
35. Tran ZV, Weltman A, Glass GV, Mood DP. The effects of exercise on blood lipids and 
lipoproteins: a meta-analysis of studies. Med Sci Sports Exerc. 1983;15(5):393-402. 
36. deFilippi CR, de Lemos JA, Tkaczuk AT, Christenson RH, Carnethon MR, Siscovick DS, et al. 
Physical activity, change in biomarkers of myocardial stress and injury, and subsequent heart failure risk 
in older adults. J Am Coll Cardiol. 2012;60(24):2539-47. 
37. Hambrecht R, Wolf A, Gielen S, Linke A, Hofer J, Erbs S, et al. Effect of exercise on coronary 
endothelial function in patients with coronary artery disease. N Engl J Med. 2000;342(7):454-60. 
38. Myers J, Prakash M, Froelicher V, Do D, Partington S, Atwood JE. Exercise capacity and mortality 
among men referred for exercise testing. N Engl J Med. 2002;346(11):793-801. 
39. Tulppo MP, Makikallio TH, Seppanen T, Laukkanen RT, Huikuri HV. Vagal modulation of heart 
rate during exercise: effects of age and physical fitness. Am J Physiol. 1998;274(2 Pt 2):H424-9. 
 22 
 
 
 
 
40. Ford ES. Does exercise reduce inflammation? Physical activity and C-reactive protein among U.S. 
adults. Epidemiology. 2002;13(5):561-8. 
41. Church TS, Barlow CE, Earnest CP, Kampert JB, Priest EL, Blair SN. Associations between 
cardiorespiratory fitness and C-reactive protein in men. Arterioscler Thromb Vasc Biol. 
2002;22(11):1869-76. 
42. Emerging Risk Factors C, Kaptoge S, Di Angelantonio E, Lowe G, Pepys MB, Thompson SG, et 
al. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual 
participant meta-analysis. Lancet. 2010;375(9709):132-40. 
43. Niebauer J, Hambrecht R, Velich T, Hauer K, Marburger C, Kalberer B, et al. Attenuated 
progression of coronary artery disease after 6 years of multifactorial risk intervention: role of physical 
exercise. Circulation. 1997;96(8):2534-41. 
44. Bouchard C, Shephard RJ, Stephens T, eds. Physical Activity, Fitness, and Health: International 
Proceedings and Consensus Statement: Champaign, III: Human Kinetics Publisher Inc; 1994. 
45. Davey Smith G, Ebrahim S. 'Mendelian randomization': can genetic epidemiology contribute to 
understanding environmental determinants of disease? International Journal of Epidemiology. 
2003;32(1):1-22. 
46. Khan H, Kunutsor S, Rauramaa R, Savonen K, Kalogeropoulos AP, Georgiopoulou VV, et al. 
Cardiorespiratory fitness and risk of heart failure: a population-based follow-up study. Eur J Heart Fail. 
2014;16(2):180-8. 
 
 
 
 23 
 
 
 
 
Figure Legends 
 
Figure 1. Hazard ratios for sudden cardiac death, fatal coronary heart disease, fatal cardiovascular 
disease, and all-cause mortality by quartiles of VO2 at AT 
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Hazard ratios were adjusted for age, body mass index, systolic blood pressure, high-density lipoprotein 
cholesterol, smoking status, alcohol consumption, prevalent coronary heart disease, history of diabetes 
mellitus, resting heart rate, physical activity, and socioeconomic status 
VO2 at AT, oxygen uptake at aerobic threshold 
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Figure 2. Hazard ratios for sudden cardiac death and fatal coronary heart disease by several participant level characteristics 
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Hazard ratios were adjusted for age, body mass index, systolic blood pressure, high-density lipoprotein cholesterol, smoking status, alcohol 
consumption, prevalent coronary heart disease, history of diabetes mellitus, resting heart rate, physical activity, and socioeconomic status; CHD, 
coronary heart disease; CI, confidence interval; HDL, high-density lipoprotein; HR, hazard ratio; SCD, sudden cardiac death; SD, standard 
deviation; VO2 at AT, oxygen uptake at aerobic threshold; *, p-value for interaction; cut-offs for age, body mass index, systolic blood pressure, 
and HDL cholesterol are based on median values. 
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Figure 3. Hazard ratios for fatal cardiovascular disease and all-cause mortality by several participant level characteristics 
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Hazard ratios were adjusted for age, body mass index, systolic blood pressure, high-density lipoprotein cholesterol, smoking status, alcohol 
consumption, prevalent coronary heart disease, history of diabetes mellitus, resting heart rate, physical activity, and socioeconomic status; CVD, 
cardiovascular disease; CI, confidence interval; HDL, high-density lipoprotein; HR, hazard ratio; sudden cardiac death; SD, standard deviation; 
VO2 at AT, oxygen uptake at aerobic threshold; *, p-value for interaction; cut-offs for age, body mass index, systolic blood pressure, and HDL 
cholesterol are based on median values. 
 26 
 
 
 
 
 
Table 1. Baseline Participant Characteristics and Correlates of VO2 at AT 
 
  
Mean (SD), median 
(IQR), or % 
Partial correlation 
r (95% CI)a 
Absolute difference (95% CI) in values 
of VO2 at aerobic threshold per 1 SD 
higher or compared to reference 
category of correlateb 
VO2 at aerobic threshold (ml/min) 1,267 (321) - - 
    
Questionnaire/Prevalent conditions    
Age at survey (years) 52.2 (5.4) -0.05 (-0.10, -0.00)* -15.90% (-31.30, -0.50)* 
Alcohol consumption (g/week) 76.0 (128.9) -0.02 (-0.07, 0.03) -6.47% (-21.91, 8.97) 
History of diabetes    
    No 96.8 - Ref 
    Yes 3.2 - -39.21% (-111.63, 33.21)** 
Smoking status    
    Other 69.0 - Ref 
    Current 31.0 - -109.01% (-141.94, -76.09)** 
History of hypertension    
    No 70.8 - Ref 
    Yes 29.2 - -21.70% (-55.74, 12.34) 
History of CHD    
    No 80.0 - Ref 
    Yes 20.0 - -123.49% (-162.23, -94.75)*** 
Use of anti-hypertensives    
    No 81.8 - Ref 
    Yes 18.2 - -127.46% (-167.54, -87.38)*** 
Medication for dyslipidemia    
    No 99.6 - Ref 
    Yes 0.4 - -114.92% (-352.75, 122.91) 
    
Physical measurements    
BMI (kg/m2) 27.0 (3.5) 0.15 (0.10, 0.19)*** 46.57% (31.31, 61.83)*** 
SBP (mmHg) 134.1 (16.4) 0.02 (-0.02, 0.07) 7.59% (-7.92, 23.09) 
DBP (mmHg) 89.4 (10.4) 0.03 (-0.02, 0.08) 8.87% (-6.54, 24.28) 
Physical activity (kj/day) 1,548 (1,436) 0.13 (0.09, 0.18)*** 42.75% (27.47, 58.03)*** 
Peak VO2 (ml/min) 2,496 (608) 0.64 (0.61, 0.67)*** 225.46% (212.53, 238.40)*** 
    
Lipid markers    
Total cholesterol (mmol/l) 5.87 (1.05) -0.07 (-0.12, -0.03)* -23.63% (-39.02, -8.23)* 
HDL-C (mmol/l) 1.28 (0.30) 0.12 (0.07, 0.17)*** 37.89% (22.59, 53.19)*** 
Triglycerides (mmol/l) 1.09 (0.78-1.54) -0.08 (-0.13, -0.03)** -26.28% (-41.76, -10.80)** 
    
Metabolic and renal markers    
Fasting plasma glucose (mmol/l) 5.33 (1.22) -0.04 (-0.09, 0.01) -12.82% (-28.25, 2.60) 
Serum creatinine (µmol/1) 89.3 (13.2) 0.07 (0.02, 0.12)* 22.34% (6.28, 38.39)* 
Estimated GFR (ml/min/1.73 m2) 87.4 (17.5) -0.06 (-0.11, -0.01)* -20.19% (-36.58, -3.81)* 
 
BMI, body mass index; CHD, coronary heart disease; CRF, cardiorespiratory fitness; DBP, diastolic blood pressure; GFR, glomerular filtration 
rate; HDL-C, high-density lipoprotein cholesterol; IQR, interquartile range; SD, standard deviation; SBP, systolic blood pressure, VO2 at AT, 
oxygen uptake at aerobic threshold; VO2max , maximal oxygen uptake; 
a , Partial correlation coefficients between VO2 at aerobic thresholds and the 
row variables;. b , Absolute change in values of VO2 at aerobic threshold per 1-SD increase in the row variable (or for categorical variables, the 
absolute difference in mean values of VO2 at aerobic thresholds for the category versus the reference) adjusted for age; asterisks indicate the level 
of statistical significance: *, p<0.05; **, p<0.01; ***, p<0.001 
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Table 2. Associations of VO2 at AT With Sudden Cardiac Death, Fatal Coronary Heart Disease, Fatal Cardiovascular Disease, and All-Cause 
Mortality  
 
Models 
Oxygen uptake at aerobic 
threshold (ml/min) 
Sudden 
cardiac death 
 Fatal coronary 
heart disease 
 Fatal 
cardiovascular 
disease 
 All-cause 
mortality 
 
 138 cases  209 cases  333 cases  719 cases  
 Hazard ratio 
(95% CI) 
p value Hazard ratio 
(95% CI) 
p value Hazard ratio 
(95% CI) 
p value Hazard ratio 
(95% CI) 
p value 
Age-adjusted         
Per 1 SD increase 0.64 (0.53-0.77) < 0.001 0.65 (0.56-0.76) < 0.001 0.75 (0.66-0.84) < 0.001 0.82 (0.75-0.88) < 0.001 
Quartile 1 (323-1053) 1 [Reference]  1 [Reference]  1 [Reference]  1 [Reference]  
Quartile 2 (1054-1228) 0.92 (0.61-1.39) 0.69 0.98 (0.70-1.38) 0.92 0.87 (0.65-1.15) 0.32 0.91 (0.74-1.10) 0.32 
Quartile 3 (1229-1470) 0.49 (0.30-0.79) 0.003 0.51 (0.35-0.75) 0.001 0.61 (0.45-0.82) 0.001 0.70 (0.57-0.85) < 0.001 
Quartile 4 (1471-2542) 0.37 (0.22-0.62) < .001 0.39 (0.25-0.59) < 0.001 0.48 (0.35-0.67) < 0.001 0.57 (0.46-0.71) < 0.001 
Multivariate-adjusted*         
Per 1 SD increase 0.70 (0.57-0.85) < .001 0.70 (0.59-0.81) < 0.001 0.79 (0.70-0.89) < 0.001 0.85 (0.79-0.92) < 0.001 
Quartile 1 (323-1053) 1 [Reference]  1 [Reference]  1 [Reference]  1 [Reference]  
Quartile 2 (1054-1228) 1.03 (0.68-1.58) 0.88 1.06 (0.75-1.49) 0.74 0.92 (0.70-1.23) 0.59 0.95 (0.78-1.16) 0.64 
Quartile 3 (1229-1470) 0.57 (0.35-0.93) 0.03 0.57 (0.39-0.85) 0.006 0.67 (0.50-0.91) 0.01 0.77 (0.62-0.94) 0.01 
Quartile 4 (1471-2542) 0.48 (0.28-0.82) 0.007 0.48 (0.31-0.74) < 0.001 0.57 (0.41-0.79) 00.001 0.66 (0.53-0.82) < 0.001 
Multivariate-adjusted* plus peak 
VO2 
        
Per 1 SD increase 0.90 (0.72-1.12) 0.34 0.87 (0.73-1.05) 0.14 0.96 (0.84-1.10) 0.54 0.97 (0.88-1.06) 0.49 
Quartile 1 (323-1053) 1 [Reference]  1 [Reference]  1 [Reference]  1 [Reference]  
Quartile 2 (1054-1228) 1.22 (0.79-1.87) 0.36 1.22 (0.86-1.73) 0.26 1.04 (0.78-1.39) 0.78 1.02 (0.84-1.25) 0.83 
Quartile 3 (1229-1470) 0.84 (0.50-1.41) 0.51 0.80 (0.53-1.22) 0.31 0.89 (0.65-1.23) 0.49 0.91 (0.73-1.13) 0.38 
Quartile 4 (1471-2542) 0.87 (0.48-1.56) 0.64 0.83 (0.52-1.34) 0.45 0.91 (0.63-1.30) 0.60 0.88 (0.69-1.12) 0.30 
 
*, Hazard ratios are adjusted for age, body mass index, systolic blood pressure, high-density lipoprotein cholesterol, smoking status, alcohol consumption, prevalent coronary heart 
disease, history of diabetes mellitus, resting heart rate, physical activity, and socioeconomic status 
VO2 at AT, oxygen uptake at aerobic threshold; VO2max, maximal oxygen uptake 
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Table 3. Associations of peak VO2 With Sudden Cardiac Death, Fatal Coronary Heart Disease, Fatal Cardiovascular Disease, and All-Cause 
Mortality  
 
Models 
VO2max (ml/min) 
Sudden 
cardiac death 
 Fatal coronary 
heart disease 
 Fatal 
cardiovascular 
disease 
 All-cause 
mortality 
 
 138 cases  209 cases  333 cases  719 cases  
 Hazard ratio 
(95% CI) 
p value Hazard ratio 
(95% CI) 
p value Hazard ratio 
(95% CI) 
p value Hazard ratio 
(95% CI) 
p value 
Age-adjusted         
Per 1 SD increase 0.44 (0.36-0.54) < 0.001 0.47 (0.40-0.55) < 0.001 0.55 (0.48-0.63) < 0.001 0.67 (0.61-0.73) < 0.001 
Quartile 1 (713-2085) 1 [Reference]  1 [Reference]  1 [Reference]  1 [Reference]  
Quartile 2 (2089-2483) 0.40 (0.27-0.61) < 0.001 0.44 (0.31-0.62) < 0.001 0.53 (0.40-0.69) < 0.001 0.65 (0.54-0.78) < 0.001 
Quartile 3 (2487-2882) 0.25 (0.15-0.42) < 0.001 0.28 (0.19-0.42) < 0.001 0.35 (0.25-0.47) < 0.001 0.52 (0.42-0.64) < 0.001 
Quartile 4 (2883-4841) 0.15 (0.08-0.28) < 0.001 0.20 (0.12-0.33) < 0.001 0.28 (0.20-0.41) < 0.001 0.42 (0.33-0.53) < 0.001 
Multivariate-adjusted*         
Per 1 SD increase 0.54 (0.43-0.67) < 0.001 0.56 (0.47-0.67) < 0.001 0.62 (0.54-0.72) < 0.001 0.73 (0.67-0.81) < 0.001 
Quartile 1 (713-2085) 1 [Reference]  1 [Reference]  1 [Reference]  1 [Reference]  
Quartile 2 (2089-2483) 0.46 (0.30-0.70) < 0.001 0.49 (0.35-0.69) < 0.001 0.56 (0.42-0.73) < 0.001 0.67 (0.55-0.81) < 0.001 
Quartile 3 (2487-2882) 0.36 (0.21-0.60) < 0.001 0.38 (0.25-0.58) < 0.001 0.43 (0.31-0.59) < 0.001 0.61 (0.49-0.76) < 0.001 
Quartile 4 (2883-4841) 0.25 (0.13-0.49) < 0.001 0.32 (0.19-0.53) < 0.001 0.39 (0.27-0.57) < 0.001 0.54 (0.42-0.69) < 0.001 
Multivariate-adjusted* plus VO2 
at AT 
        
Per 1 SD increase 0.57 (0.44-0.74) < 0.001 0.60 (0.49-0.75) < 0.001 0.64 (0.54-0.75) < 0.001 0.75 (0.67-0.84) < 0.001 
Quartile 1 (713-2085) 1 [Reference]  1 [Reference]  1 [Reference]  1 [Reference]  
Quartile 2 (2089-2483) 0.49 (0.32-0.75) 0.001 0.53 (0.37-0.75) < 0.001 0.58 (0.44-0.76) < 0.001 0.69 (0.57-0.84) < 0.001 
Quartile 3 (2487-2882) 0.41 (0.24-0.71) 0.001 0.46 (0.29-0.71) 0.001 0.46 (0.33-0.65) < 0.001 0.65 (0.52-0.82) < 0.001 
Quartile 4 (2883-4841) 0.32 (0.15-0.66) 0.002 0.43 (0.24-0.75) 0.003 0.45 (0.29-0.69) < 0.001 0.61 (0.46-0.80) < 0.001 
 
*, Hazard ratios are adjusted for age, body mass index, systolic blood pressure, high-density lipoprotein cholesterol, smoking status, alcohol consumption, prevalent coronary heart 
disease, history of diabetes mellitus, resting heart rate, physical activity, and socioeconomic status 
VO2 at AT, oxygen uptake at aerobic threshold 
 
 
